Physician profile
Tyler Nelson
NPI 1306814546
$8,960.69
in general payments reported to CMS, 2019-2025
50 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $1,202 · 2021: $1,589 · 2022: $1,248 · 2023: $1,394 · 2024: $1,060 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,487.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,352.15 | 2021-2025 | |
| Amgen INC. | $965.30 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $812.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $449.06 | 2019-2025 | |
| Novo Nordisk INC | $406.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $357.83 | 2019-2022 | |
| Dexcom, INC. | $338.96 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.74 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.80 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $298.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $258.46 | 2022-2025 | Freestyle Libre 3, Eterna |
| Merck Sharp & Dohme LLC | $251.09 | 2019-2021 | |
| Merz North America, INC. | $250.00 | 2023 | |
| Allergan, INC. | $235.16 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.95 | 2024-2025 | Caplyta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.